A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer

Study Status

Closed to Enrollment

Study Description

This phase II trial is studying the side effects of giving temsirolimus together with bevacizumab and to see how well it works in treating patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor.

Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

Disease Status and/or Stage

Locally Advanced, Recurrant or Metastatic disease


Mayo Clinic, National Cancer Institute

Key Eligibility

  • Men and women age 18 and over
  • Diagnosed with:
    • Endometrial Cancer
    • Gastrointestinal Carinoid Tumor
    • Islet Cell Tumor
    • Liver Cancer
    • Lung Cancer
    • Ovarian Cancer
  • Locally advanced, recurrent or metastatic disease
  • Additional eligibility criteria to be discussed when you contact the study team

Principal Investigator

Elizabeta Popa, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page